Phase II study of the thymidylate synthetase inhibitor CB3717 (N10-propargyl-5,8-dideazafolic acid) in colorectal cancer

Br J Cancer. 1988 Jun;57(6):628-9. doi: 10.1038/bjc.1988.143.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Colonic Neoplasms / drug therapy*
  • Drug Evaluation
  • Female
  • Folic Acid / adverse effects
  • Folic Acid / analogs & derivatives*
  • Folic Acid / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Quinazolines / adverse effects
  • Quinazolines / therapeutic use*
  • Rectal Neoplasms / drug therapy*

Substances

  • Antineoplastic Agents
  • Quinazolines
  • CB 3717
  • Folic Acid